On June 10, 2021 Immunicom, Inc., a global biotech company reported that it is redefining immuno-oncology with breakthrough non-pharmaceutical subtractive immunotherapy treatments designed to preserve quality-of-life while being treated, presented preliminary data from its late-stage, metastatic triple-negative breast cancer (mTNBC) clinical trial at the American Association of Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting 2021 (Press release, Immunicom, JUN 10, 2021, View Source [SID1234583843]). AACR (Free AACR Whitepaper)’s Annual Meeting is one of the world’s premier scientific gatherings of cancer specialists and researchers, attracting more than 20,000 participants annually.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Immunicom is investigating its FDA-designated breakthrough Immunopheresis therapy, which is a filtration-based subtractive treatment designed to capture sTNF-R proteins that are shed by cancer cells and inhibit a patient’s natural anti-tumor immune activity. Immunicom presented data for the first cohort of mTNBC patients treated with Immunopheresis which showed an 80% decrease of the inhibitory sTNF-R proteins and observed a sustained quality-of-life while on therapy with minimal side effects.
"Current cancer treatments have significant toxicities and can dramatically diminish a patient’s quality-of-life, especially in patients with late-stage disease that have received multiple prior courses of therapy," said Amir Jafri, Immunicom CEO and Founder. "We are studying an innovative emerging therapy which could signal a new era for cancer treatment that employs a novel immunotherapeutic approach which is especially well-tolerated by these fragile patients."
Immunicom’s presentation "Extracorporeal pulldown of soluble TNFRs to unleash the activity of endogenous TNFα in chemorefractory triple-negative breast cancer patients – first-in-human experience" was presented by the study’s Chief Investigator, Piotr Wysocki, MD, PhD, Department Head of Oncology at the Jagiellonian University – Medical College Hospital in Krakow and President of the Polish Society of Clinical Oncology, and will be available online until June 21, 2021, details as follows:
View Source!/9325/presentation/5206